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SUMMARY
We developed a transgenic mouse expressing the HER2V777L
activating mutation in the intestines. HER2V777L expression
resulted in hypertrophic crypt formation, hyperplasia, and
intermediate cell formation on intestinal villi. Mutation of
both APC and HER2 enhanced proliferation of intestinal
crypts.
BACKGROUND AND AIMS: The Cancer Genome Atlas (TCGA)
project has identified HER2 mutations or amplification in 7% of
colon cancers. In addition to HER2 mutations, colon cancer
patients also possess co-occurring mutations in genes such as
APC. Here, we investigated the role of HER2 and APC mutations
on the crypt-villus architecture of the intestinal epithelium,
localization of secretory cells, and expression of intestinal stem
cell markers.
METHODS: We generated a HER2 transgenic mouse
(HER2V777L Tg) possessing an activating mutation commonly
found in colorectal cancer patients, HER2V777L, using tran-
scription activator-like effector nucleases–based gene editing
technology. We expressed the HER2V777L transgene in mouse
small intestine and colon using Lgr5-Cre and Villin-Cre
recombinases. In addition, we analyzed Lgr5-Cre; APCmin;
HER2V777L Tg mice by morphologic and gene expression assays
on intestinal sections and organoids derived from the
epithelium.
RESULTS: HER2V777L expression resulted in hypertrophic crypt
formation with expanded zones of proliferation. Proximal in-
testinal villi showed increased abundance of multiple differ-
entiated lineages including extensive intermediate cell
differentiation, as evidenced by MUC2/MMP7 co-
immunofluorescence and transmission electron microscopy.
HER2V777L expression in the context of APC loss resulted in
further enhancement and expansion of the proliferative crypt
compartment.
CONCLUSIONS: We established an epithelial intrinsic role for
HER2V777L on enhanced cellular proliferation. Additionally, we
determined that HER2 and APC mutations, when combined,
promote enhanced proliferation of intestinal crypts. (Cell Mol
Gastroenterol Hepatol 2021;12:1105–1120; https://doi.org/
10.1016/j.jcmgh.2021.04.012)
Keywords: Colorectal Cancer; Intestinal Organoids; Intermedi-
ate Cells.
The intestinal epithelium is tightly regulated by theexpression of several growth factors produced
within the stem cell niche that control intestinal cell pro-
liferation and differentiation. For example, members of the
epidermal growth factor receptor (EGFR) family (human
epidermal growth factor receptor 2 [HER2], HER3, and
HER4) are commonly expressed throughout the intestinal
epithelium and regulate cell migration, survival, and differ-
entiation.1 Furthermore, overexpression of these receptor
tyrosine kinases is known to result in poor outcomes in
several gastric and other solid tumors types.2,3 Further
study of these receptor tyrosine kinases is needed to
delineate their role in cancer development.
Recent studies by The Cancer Genome Atlas colorectal
cancer project have identified 7% of colorectal cancer (CRC)
patients with HER2 mutations or amplification.4 In vitro
characterization of HER2 mutations has identified several
activating mutations, such as V777L and V842I that activate
downstream signaling pathways in colon cancer cell lines
and confer anchorage-independent growth in soft agar as-
says.5 As a result, HER2 mutations are thought to play a
crucial role in cancer development; however, the precise
role that these mutations play on the intestinal epithelium
has not been determined.
Prior studies on EGFR family members have determined
that these receptors play crucial roles in promoting growth
and proliferation. For example, in vivo expression of EGFR
was found to be crucial for promoting intestinal cell pro-
liferation and tumor initiation.6 Additionally, expression of
HER3 in the intestinal epithelium has been found to pro-
mote wound healing following chemically induced colitis,
tumorigenesis, and differentiation of secretory cell types,
such as Paneth cells.7–9 Similarly, studies examining the role
of HER2 expression in the intestinal epithelium have iden-
tified that HER2 plays a role in recovery of chemically
induced colitis.7 However, additional in vivo studies of HER2
are limited and the role of an activating HER2 mutation on
intestinal epithelial architecture has not been previously
determined. As a result, we sought to determine the role of
an activating HER2 mutation, HER2V777L, on the crypt-villus
architecture of the intestinal epithelium. Additionally, we
also characterized gene expression changes in stem cells
and secretory marker genes induced by expression of our
HER2V777L transgene. Last, we also sought to examine the
role of HER2V777L on tumor formation and CRC progression
using an APCmin mouse model.
We demonstrated that in vivo expression of HER2V777L
in the proximal small intestine resulted in hyperplasia,
expansion of intestinal crypts, increased expression of stem
cell markers, and intermediate cell formation on the villi.
Furthermore, HER2V777L expression, in the context of
adenomatous polyposis coli (APC) loss, further enhanced
proliferation of small intestinal crypts. These data provide
the first insight into the role of HER2V777L expression on
intestinal epithelial homeostasis and stem cell populations.
Results
HER2V777L Expression Driven by Lgr5-CreERT2
Enhances Crypt Depth and Villus Length
HER2 transgenic (Tg) mice expressing the Lox-STOP-Lox
HER2V777L transgene (HER2V777L Tg) were generated using
transcription activator-like effector nucleases (TALEN)–
based gene editing (Figure 1A). The HER2V777L mutation is a
constitutively activated mutation that has been identified in
human colorectal cancer patients.5 Because CRC arises from
intestinal stem cells, we utilized the Lgr5-CreERT2 mouse
strain, which expresses Cre-recombinase in the Lgr5-
positive crypt-base columnar stem cells to activate
HER2V777L expression.10,11
To assess the role of HER2V777L expression on the in-
testinal epithelium, 2-month-old Lgr5-Cre; HER2V777L Tg
and littermate control mice were treated with tamoxifen
for 3 consecutive days and sacrificed 10 days after the last
injection (Figure 1B). Increased phosphorylation of HER2
and increased total HER2 were observed by western
blotting in jejunal and colonic tissue lysates from Lgr5-Cre;
HER2V777L Tg mice relative to littermate control mice
treated with tamoxifen (Figure 1C). The Lgr5-CreERT2
mouse is known to give mosaic or variegated Cre expres-
sion in the intestine11 and we found that approximately
60% of small intestinal crypts and villi had strong
HER2V777L expression. HER2V777L transgene expression
resulted in hypertrophic crypt formation in the proximal
small intestine, distal small intestine, proximal colon, and
distal colon relative to littermate control mice
(Figure 1D–G). In the mucosal folds of the proximal colon,
HER2V777L expression also triggered remodeling of the
epithelium with a transformation of flat, crypt cuffs (in
control mice) into finger-like projections resembling villi
(Figure 1F). This phenotype was less pronounced in the
distal colon of HER2V777L mice, where expression of HER2
showed greater variegation compared with proximal in-
testinal areas (Figure 1G). HER2V777L nonexpressing crypts
or villi in the small intestine and colon were morphologi-
cally identical to littermate control mice. The observed
hypertrophic phenotype in the intestine was also illus-
trated by enhanced crypt depth in Lgr5-Cre; HER2V777L Tg
mice in the proximal small intestine, distal small intestine,
proximal colon, and distal colon (Figure 1H). HER2V777L
expression also resulted in an expanded zone of prolifer-
ating cells as measured by Ki-67 staining in all regions of
the intestine (Figure 1I). Proximal small intestinal crypts of
Abbreviations used in this paper: APC, adenomatous polyposis coli;
CRC, colorectal cancer; EGFR, epidermal growth factor receptor;
HER, human epidermal growth factor receptor; MAPK, mitogen-acti-
vated protein kinase; mRNA, messenger RNA; qRT-PCR, quantitative
reverse-transcription polymerase chain reaction; TALEN, transcription
activator-like effector nucleases; Tg, transgenic.
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Lgr5-Cre; HER2V777L Tg mice also showed increased
phosphorylated mitogen-activated protein kinase
(p-MAPK), a known downstream signaling protein of
HER2, via immunofluorescence staining (Figure 1L). Last,
HER2V777L expression was also associated with enhanced
villus length in the proximal and distal small intestine
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relative to control mice (Figure 1J and K). These findings
demonstrate that HER2V777L expression resulted in
morphologic alterations of both proliferative and differen-
tiated compartments of the intestine.
HER2V777L Expression Increases Intestinal Stem
Cell Markers and Expression of Wnt Target
Genes in the Proximal Small Intestine
Due to the enhanced crypt depth in Lgr5-Cre; HER2V777L
Tg mice, we next examined whether expression of intestinal
stem cell markers in the proximal jejunum were altered
using quantitative reverse-transcription polymerase chain
reaction (qRT-PCR). Messenger RNA (mRNA) expression of
the stem cell markers, Bmi1, Olfm4, and Lrig1 were
increased in Lgr5-Cre; HER2V777L Tg mice relative to control
mice, whereas expression of Lgr5 did not significantly
change in these same mice (Figure 2A). One possible
explanation for this difference in Lgr5 compared with other
stem cell markers is that the Lgr5 Cre-recombinase allele
results in knock-out of 1 copy of the Lgr5 gene. Other Wnt
target genes such as Axin2, Cd44, and c-Myc showed
elevated mRNA expression in Lgr5-Cre; HER2V777L Tg mice
(Figure 2B). These qRT-PCR measurements represent a
population average across the HER2V777L expressing and
nonexpressing regions of the epithelium. Taken together,
our data suggest that HER2V777L expression enhances Wnt
signaling and markers of intestinal stem cells that may
provide an explanation for the enhanced crypt depth
observed in these mice.
HER2V777L Expression Promotes Enhanced
Expression of Secretory and Absorptive Markers
in the Proximal Small Intestine
Given the differences observed in the stem cell popula-
tion of Lgr5-Cre; HER2V777L Tg mice, we next examined
expression of markers of differentiated epithelial lineages.
We found evidence that mRNA markers for differentiation of
4 major cell types were altered in Lgr5-Cre; HER2V777L Tg
mice. A Paneth cell marker, lysozyme, and goblet cell
markers, Muc2 and Tff3, showed increased expression in
Lgr5-Cre; HER2V777L Tg mice, relative to littermate control
mice, whereas expression of Defcr5 (another Paneth cell
marker) remained unchanged. Additionally, expression of
markers for enteroendocrine cell lineages, chromogranin A
and neurog3, was also enhanced in Lgr5-Cre; HER2V777L Tg
mice (Figure 2C). Interestingly, the absorptive cell markers,
Alpi and Fabp1, were increased in Lgr5-Cre; HER2V777L Tg
mice (Figure 2D). The increase in secretory and absorptive
markers was accompanied by increased expression of the
transcription factors Atoh1, Hes1, and Gfi1, suggesting that
HER2V777L promotes intestinal differentiation (Figure 2E).
Overall, our data suggest that HER2V777L expression in the
proximal small intestine promotes a concomitant secretory
cell hyperplasia as well as enhanced expression of absorp-
tive markers, which is consistent with the increased villus
height observed in our Tg mouse model.
In contrast to the increased stem cell markers observed
in the small intestine, significant changes in Bmi1 or Olfm4
expression were not observed in the colon tissue of Lgr5-
Cre; HER2V777L Tg mice. This result is largely due to the
absence of Bmi1 or Olfm4 expression in the colon
(Figure 2F). However, decreased expression of the stem cell
markers Lrig1 and Lgr5 were observed, suggesting that
HER2V777L expression limits expansion of stem cell pop-
ulations in the colon. In addition, HER2V777L expression also
resulted in decreased expression of Wnt target genes, Axin2,
Cd44, and c-Myc, which contrasted the enhanced expression
of Wnt target genes observed in the small intestine
(Figure 2G). Expression of the secretory cell marker, Muc2
was also decreased in Lgr5-Cre; HER2V777L colon organoids,
suggesting that HER2V777L expression in the colon alters
differentiation of secretory cells (Figure 2H). Last, expres-
sion of the absorptive marker, Alpi, was increased in Lgr5-
Cre; HER2V777L colon tissue, whereas expression of the
transcription factors Hes1 and Gfi1 were decreased
(Figure 2I and J, respectively). As a result, HER2V777L
expression in the colon resulted in decreased expression of
stem cell markers and altered differentiation, which con-
trasted the phenotype observed in the small intestine.
Additionally, the expression changes in stem cell and
secretory cell markers induced by HER2V777L in the colon
also may reflect spatial and functional differences between
the small intestine and colon.
HER2V777L Expression Increases Absorptive Cells
and Promotes Intermediate Cell Formation in the
Proximal Small Intestine
We next assessed relative cellular abundance of intes
tinal epithelial stem, Paneth, goblet, and absorptive cells
Figure 1. (See previous page). HER2V777L expression confers hypertrophic crypt formation in vivo. (A) Schematic for
design of HER2V777L Tg mouse. (B) Lgr5-Cre; HER2V777L and HER2V777L littermate mice were treated with tamoxifen at 8
weeks of age for 3 consecutive days and sacrificed 10 days after the last injection. (C) Western blotting from jejunum and colon
tissues for phospho-HER2 and total HER2 from tamoxifen-treated mice. (D–G) HE, HER2, and Ki-67 images of proximal small
intestine, distal small intestine, proximal colon, and distal colon tissue sections from Lgr5-Cre; HER2V777L Tg and littermate
control mice, respectively. Scale bars are 50 mm. (H) Quantification of crypt depth for proximal small intestine, distal small
intestine, proximal colon, and distal colon as measured in micrometers. Eighty HER2 expressing crypts per mouse were
measured and n  4 per group. (I) Quantification of Ki-67 positive cells per crypt and n  4 per group (J) HE and HER2 staining
of Lgr5-Cre; HER2V777L Tg and littermate control villi. (K) Quantification of villus length for proximal and distal small intestine.
Eighty HER2 expressing villi per mouse were measured and n ¼ 3 per group. Data are plotted as means, 1 dot represents 1
mouse, and mean ± SEM are reported. **P < .01, ***P < .001, and ****P < .0001 as calculated by the Student t test. (L)
Representative grayscale images of phosphorylated MAPK (p-MAPK) immunofluorescence staining of the proximal small
intestine of littermate control and Lgr5-Cre; HER2V777L mice. Scale bars are 100 mm.
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in the proximal jejunum using immunohistochemistry.
Expression of Olfm4, a crypt-based columnar marker, was
expanded throughout Lgr5; Cre-HER2V777L Tg crypts,
suggesting that Olfm4 expressing stem cells were
expanded in our mouse model (Figure 3A). Paneth cells at
crypt bases were decreased relative to littermate control
Figure 3. HER2V777L
expression decreases
Paneth cell number per
crypt. (A) Immunohisto-
chemistry staining for
Olfm4 in the proximal small
intestine of Lgr5-Cre;
HER2V777L Tg and litter-
mate control mice. Repre-
sentative images are




Schiff (PAS), and Fabp1 of
Lgr5-Cre; HER2V777L Tg
and littermate control
mice. Scale bars are 50
mm. (C) Quantification of
Paneth cell number per
crypt, (D) PAS-positive
cells per crypt, and (E)
Fabp1-positive cells per
crypt. Eighty crypts were
measured and n  3 per
group.
Figure 2. (See previous page). HER2V777L expression increases intestinal stem cell populations and expression of
absorptive markers. Small intestinal tissue from Lgr5-Cre; HER2V777L Tg and littermate control mice were examined for the
expression of (A) stem cell markers, (B) Wnt target genes, (C) secretory cell markers, (D) absorptive markers, and (E) Notch
target genes via qRT-PCR. Colon tissue from Lgr5-Cre; HER2V777L Tg and littermate control mice were examined for the
expression of (F) stem cell markers, (G) Wnt target genes, (H) secretory cell markers, (I) absorptive markers, and (J) Notch target
genes via qRT-PCR. 18s ribosomal RNA was used as a reference gene. n ¼ 3 mice per group, with 2 or 3 technical replicates
performed for each mice. Data are plotted as mean ± SEM, 1 dot represents 1 data point. *P < .05, **P < .01, ***P < .001, and
****P < .0001 as calculated by the Mann-Whitney U test.
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Figure 4. HER2V777L expression increases intermediate cells per villi in the small intestine. (A) Immunohistochemistry
staining for lysozyme and PAS on intestinal villi. Scale bars are 100 mm. (B) Quantification of Paneth cell number per villus and
(C) quantification of PAS-positive cells per villus. Eighty intestinal villi were measured; n ¼ 4 per group. (D) Representative
immunofluorescence staining of the proximal small intestine of Lgr5-Cre; HER2V777L Tg and littermate control mice using
MUC2 (red) and MMP7 (green) and merged images (with DAPI, blue). Yellow-colored cells indicate presence of intermediate
cells with green and red colors merged. Scale bars are 100 mm. (E) Quantification of intermediate cells for the proximal small
intestine. More than 50 villi were counted per mouse and n ¼ 2 per group. (F) Transmission electron microscopy (TEM)
representative images of goblet cells on the villi, Paneth cell at the base of the crypt, and intermediate cells near the crypt
from Villin-Cre; HER2V777L Tg mice. Scale bars are 2 mm.
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mice, as assessed by lysozyme and periodic-acid Schiff
staining (Figure 3B–D). Lgr5-Cre; HER2V777L Tg mice
also possessed increased numbers of enterocytes as
assessed by Fabp1 staining (Figure 3B and E), which
correlated with the mRNA expression data shown in
Figure 2D.
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Interestingly, although Paneth cells were reduced per
crypt, the number of lysozyme positive cells was enhanced
along villi (Figure 4A and B). Additionally, goblet cell num-
ber was increased in Lgr5-Cre; HER2V777L Tg villi relative to
littermate control mice (Figure 4A and C). Morphologically,
the lysozyme positive cells observed on the villus showed
dual staining for goblet and Paneth markers (MMP7 and
MUC2), indicating that these cells may be intermediate cells
(Figure 4D and E).12,13 Furthermore, transmission electron
microscopy of jejunum-derived intestinal crypts also iden-
tified intermediate cells, which are characterized by the
presence of apical mucin granules that each contain a single
electron dense foci within them (Figure 4F; last panel).
These granules were distinct in morphology from goblet or
Paneth cells in control mice (Figure 4F; first 2 panels).
Overall, we determined that HER2V777L expression pro-
motes intermediate cell formation on intestinal villi.
HER2V777L Expression In Vitro Confers Enhanced
Small Intestinal Organoid Budding and Increased
Expression of Stem Cell Markers
Next, to determine whether the enhanced growth
phenotype observed in vivo is epithelial cell intrinsic or cell
extrinsic, we utilized primary small intestinal epithelial
organoid cultures. We generated organoids from the prox-
imal jejunum of Lgr5-Cre; HER2V777L Tg mice, confirmed
their HER2V777L expression, and observed changes in
morphology. Lgr5-Cre; HER2V777L Tg organoids possessed
increased number of buds after growth in EGF, Noggin, and
R-spondin media over a 4-day period relative to littermate
control organoids, which correlated with the enhanced crypt
size observed in vivo (Figure 5A–C). Organoid forming effi-
ciency was not significantly enhanced by HER2V777L
expression, suggesting that HER2V777L expression increases
budding after initial formation of organoids (Figure 5D).
Last, to determine whether the enhanced growth phenotype
was due to enhanced downstream signaling, immunoblot-
ting of small intestine organoids derived from tamoxifen-
treated mice was performed. HER2V777L expression
resulted in a modest increase in MAPK phosphorylation and
did not change Akt signaling (Figure 5E). Treatment of the
intestinal organoid cultures with a MEK inhibitor, TAK-733,
reduced organoid budding, supporting a partial role for the
MEK-MAPK pathway in this phenotype. However, we found
that higher doses of this inhibitor decreased organoid
viability, likely due to the fact that the MEK-MAPK pathway
is involved in many essential signal pathways (Figure 5F).
Last, owing to the enhanced budding phenotype observed,
we also sought to determine whether expression of stem
cell and secretory cell markers were enhanced in our in-
testinal organoid model. Similar to the trends observed in
small intestine tissue, HER2V777L expression resulted in
increased expression of the stem cell markers, Bmi1, Lrig1,
and Olfm4 but not Lgr5 (Figure 5G). The increase in stem
cell markers was also accompanied by an increase in Wnt
target genes, which suggests that enhanced Wnt signaling
may play a role in the expansion of stem cells observed
(Figure 5H). Last, HER2V777L expression also conferred
increased expression of all secretory cell types examined as
well as increased expression of absorptive markers and
Notch target genes, which correlated with the trends
observed in the small intestinal tissue (Figure 5I–K). As a
result, the stem cell and absorptive cell phenotypes
observed in the small intestine in vivo can be recapitulated
in our intestinal organoid culture model, supporting that the
in vivo phenotypes are epithelial cell autonomous.
HER2V777L Expression in Colon Organoids Does
Not Alter Organoid Morphology and Decreases
Expression of Stem Cell Markers
Last, owing to the distinct morphological changes
observed in the small intestine, we also sought to examine
the effect of HER2V777L expression on proximal colon
organoids derived from Lgr5-Cre; HER2V777L Tg mice.
HER2V777L expression did not result in changes in colon
organoid morphology, perhaps owing to the highly prolif-
erative Wnt, R-spondin, and Noggin media used to culture
the colon organoids (Figure 6A). An increase in total
HER2V777L expression was confirmed by western blotting in
the Lgr5-Cre; HER2V777L Tg colon organoids derived from
tamoxifen-treated mice; however, significant changes in
MAPK or Akt phosphorylation were not observed
(Figure 6B). Last, we utilized quantitative PCR analysis to
assess changes in the expression levels of stem cell, secre-
tory cell, and absorptive marker genes in proximal colon-
derived organoid cultures. The expression levels of the
stem cell markers Bmi1 and Lgr5 and Wnt-target genes
Cd44 and c-Myc were decreased in colon organoids derived
from tamoxifen-treated Lgr5-Cre; HER2V777L Tg mice rela-
tive to littermate control mice (Figure 6C and D). In
Figure 5. (See previous page). Expression of HER2V777L in small intestinal organoids confers enhanced budding and
increased expression of stem cell and absorptive markers. (A) Representative image of small intestinal organoids
generated from the jejunum of Lgr5-Cre; HER2V777L Tg and control mice grown over a 4-day period in EGF, noggin, and
R-spondin media. (B) Higher magnification image of intestinal organoid cultures are shown. Scale bars are 500 mm. (C)
Quantification of the average number of buds per organoid. Three technical replicates are shown and n ¼ 3 mice per group for
Lgr5-Cre; HER2V777L Tg organoids. (D) Quantification of organoid forming efficiency in intestinal organoids derived from the
jejunum of Lgr5-Cre; HER2V777L Tg and littermate control mice after 3 days in culture. (E) Western blot for phospho-HER2 and
total HER2 from indicated mice. (F) Treatment of Lgr5-Cre; HER2V777L Tg–derived jejunum organoids with TAK-733 for 4 days.
Cell viability was >80% at 100 nM and approximately 50% at 500 nM TAK-733. Small intestinal organoids from Lgr5-Cre;
HER2V777L Tg and littermate control mice were examined for the expression of (G) stem cell markers, (H) Wnt target genes, (I)
secretory cell markers, (J) absorptive cell markers and (K) Notch target genes via qRT-PCR. 18s ribosomal RNA was used as a
reference gene. n  3 per group. Technical duplicate or triplicate for each mice. Data are plotted as mean ± SEM, 1 dot
represents 1 data point. *P < .05, **P < .01, ***P < .001, and ****P < .0001 as calculated by the Mann-Whitney U test.
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addition, significant changes in the expression of goblet cell
and enteroendocrine cell markers Tff3 and ChgA were
observed in colon organoids derived from Lgr5-Cre;
HER2V777L mice (Figure 6E). In contrast, increased expres-
sion of Alpi, an absorptive marker, was also observed in
Lgr5-Cre; HER2V777L organoid cultures (Figure 6F). The
increased expression of absorptive markers observed also
likely reflects the abundance of absorptive cells normally
present in the colon. Overall, HER2V777L expression in colon
organoids did not result in expansion of the stem cell
Figure 6. Colon organoids from Lgr5-Cre; HER2V777L Tg and littermate control mice. (A) Representative image of colon
organoids generated from Lgr5-Cre; HER2V777L Tg and littermate control mice grown in 50% L-WRN conditioned media. Scale
bars are 200 mm. (B) Western blot for phospho-HER2 and total HER2 from indicated mice treated with tamoxifen in vivo. Colon
organoids from Lgr5-Cre; HER2V777L Tg and littermate control mice were examined for the expression of (C) stem cell markers,
(D) Wnt-target genes, (E) secretory cell markers, (F) absorptive cell markers, and (G) Notch target genes via qRT-PCR. 18s
ribosomal RNA was used as a reference gene. n ¼ 3 mice per group, with 2 or 3 technical replicates performed for each mice.
Data are plotted as mean ± SEM, 1 dot represents 1 data point. *P < .05, **P < .01, ***P < .001, and ****P < .0001 as
calculated by the Mann-Whitney U test.
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population, and distinct changes in organoid morphology
were not observed as a result.
APC Loss Combined With Short-Term
HER2V777L Expression Generates a
Hyperproliferative Phenotype in Intestinal Crypts
Next, we examined the role of co-occurring mutations on
tumorigenesis using our HER2V777L Tg mouse model. Colo-
rectal cancer patients possessing HER2 missense mutations
possess several co-occurring mutations in tumor suppressor
genes such as APC, TP53, and oncogenes such as, KRAS and
PIK3CA (Figure 7A).14 Of these co-occurring mutations,
HER2 and APC mutations were the most prevalent, and we
sought to examine the role of both HER2 and APC mutations
on tumor progression using an APCmin mouse model. Lgr5-
Cre; HER2V777L Tg mice were crossed with heterozygous
APCmin mice to generate Lgr5-Cre; APCmin; HER2V777L Tg
mice and these mice were treated with tamoxifen at 8 weeks
of age and sacrificed 10 days after the last injection to study
short-term changes induced by APC and HER2 mutations.
Intestinal adenomas in Lgr5-Cre; APCmin; HER2V777L Tg
mice and Lgr5-Cre; APCmin control mice were also analyzed
via immunohistochemistry staining. Surprisingly, HER2V777L
expression did not result in significant increases in the
number of Ki-67–positive cells per adenoma, average ade-
noma size, or number per mouse (Figure 7B–E). However,
Lgr5-Cre; APCmin; HER2V777L Tg mice possessed several
hyperproliferative regions characterized by proliferative
Figure 7. HER2V777L expression promotes hyperproliferation in the context of APC loss. (A) Colon adenocarcinoma
(COAD) or rectum adenocarcinoma (READ) patients were extracted from The Cancer Genome Atlas Unified Ensemble call set
resulting in a total of 559 patients. All COAD (blue) and READ (light blue) patients found to have missense mutations in ERBB2
that co-occur with any other mutation type in a subset of genes are highlighted on the left. (B) Immunohistochemistry staining
for HER2 and Ki-67 in intestinal adenomas of Lgr5-Cre; APCmin; HER2V777L Tg and Lgr5-Cre; APCmin mice. Scale bars are 100
mm. (C) Quantification of the average number of Ki-67–positive cells per adenoma. n ¼ 3 per group. (D) Average adenoma size
per mouse as measured in micrometers. n  3 per group. (E) Quantification of adenoma number per mouse (proximal and
distal small intestine). n ¼ 3 per group. (F) Immunohistochemistry staining for HER2 and Ki-67 in hyperproliferative crypts.
Scale bars are 100 mm. No significant differences measured by t test in C–E.
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crypts that protrude toward villus tips (Figure 7F). These
hyperproliferative regions were not observed in Lgr5-Cre;
APCmin control mice. Overall, we determined that HER2 and
APC mutations promote a hyperproliferative environment
that may promote a tumor initiating phenotype, rather than
tumor progression. Co-occurring mutations in TP53 and the
SMAD pathway are likely needed to observe cancerous
phenotypes.
Discussion
Roughly 7% of colon cancer patients possess HER2
mutations or amplification. Previous research has identified
several HER2 mutations in the kinase domain that activate
downstream signaling pathways and confer enhanced
growth, such as HER2V777L.5 Our work is the first to char-
acterize the role of HER2V777L expression on the intestinal
epithelium using Tg mice. We hypothesized that expression
of HER2V777L would promote crypt hyperplasia and
enhanced proliferation due to the role of HER2 and other
EGFR family members on cell growth and proliferation us-
ing in vitro models.15,16 Prior studies exploring the role of
HER2 on the intestinal epithelium have determined that
HER2 does promote intestinal epithelial recovery from
injury, but intestinal epithelial knockout of HER2 does not
alter intestinal crypt or villus morphology, proliferation, or
migration, possibly because of functional overlap with
HER3.7 Similarly, additional studies on the role of HER3
determined that expression of this receptor does not alter
intestinal proliferation or migration, and that these re-
ceptors instead play crucial roles during tumorigenesis.8
The results presented using our HER2 Tg mouse model,
however, illustrate for the first time, the role of an activating
HER2V777L mutation on intestinal epithelial homeostasis and
crypt-villus architecture.
Using our Tg mouse model, we determined that
HER2V777L expression in the proximal small intestine
increased crypt depth and villus length via enhanced pro-
liferation and expansion of progenitor stem cells. In
contrast, expression of HER2V777L in the proximal colon
resulted in abnormal morphology of the mucosal folds;
however, increased expression of stem cell and secretory
cell markers were not observed as a result of HER2V777L
expression. As a result, expression of HER2V777L has dif-
ferential effects on stem cell and secretory cell populations
depending on the region of the intestine, and the strongest
phenotypes induced by our mouse model were observed in
the small intestine. In addition, the enlarged crypt pheno-
type observed in our mouse model is similar to mouse
models expressing the KRAS G12D mutation, wherein a
similar expanded crypt phenotype is characterized by
increased proliferation via enhanced MAPK signaling and
increased Hes1 expression.17 Underlying mechanisms for
the hyperproliferative phenotypes observed in our Tg
mouse model are likely due to enhanced activation of
phosphorylated MAPK in the proximal small intestine as
assessed by immunofluorescence staining and increased
expression of the Notch transcription factors Hes1 and Gfi1;
however, additional studies are needed to confirm potential
mechanisms. We also assessed whether the hyper-
proliferative phenotypes observed in vivo could be reca-
pitulated using intestinal organoid cultures. HER2V777L
expression in intestinal organoids conferred an increase in
bud number due to an increase in stem cell markers as
determined by quantitative PCR. Prior studies assessing the
role of Lrig1, a negative regulator of EGFR signaling, have
also determined that knockout of Lrig1 also results in an
increased number of organoid buds due to increased
expression of HER2 and HER3.18
In addition, we also determined that HER2V777L expres-
sion promotes intermediate cell formation on the intestinal
villi. One potential mechanism for this effect is through the
Rho family GTPases, Rac1 and Cdc42. HER2 is known to
signal to Rac1 and Cdc42 through p120 Catenin,19 and
modulation of Rac1 or Cdc42 has been shown to alter
Paneth and goblet cell differentiation.13,20 Introduction of a
dominant negative Rac1 mutant in the intestinal epithelium
resulted in increased intermediate cells, decreased mature
goblet cells, and a less prominent reduction in Paneth cells,
whereas introduction of constitutively active Rac1 mutant
caused precocious differentiation of Paneth cells and
enterocytes.13 Likewise, knockout of Cdc42 also increased
intermediate cell formation.20 Notch blockade has also been
shown to increase intermediate cell formation21; however,
expression of the HER2V777L transgene resulted in increased
expression of the Notch transcription factor, Hes1, in the
jejunum, suggesting that Notch signaling inhibition is not
the cause of increased intermediate cell formation observed
in HER2V777L Tg mice.
Last, our studies to examine the role of HER2 and APC
mutations on tumorigenesis illustrated that HER2V777L
expression lead to a hyperproliferative phenotype in Lgr5-
Cre; APCmin; HER2V777L Tg mice. Our experiments focus on
acute changes induced by HER2V777L expression and our
work does not attempt to explore how HER2V777L expres-
sion could be impacting tumor progression over a longer
time period, and thus we did not observe an increase in the
number or size of intestinal adenomas in Lgr5-Cre; APCmin;
HER2V777L Tg mice in the acute time frame. Our results
complement longer-term studies on the role of EGFR family
members on tumorigenesis, which showed that genetic
inactivation of EGFR or HER3 significantly decreases tumor
formation in APCmin mouse models, suggesting that these
receptors play important roles in tumor formation.6,8
Additionally, expression of our HER2V777L transgene might
require additional mutations, such as in p53 and SMAD
genes, for progression of adenomas to carcinomas.
In summary, we determined that HER2V777L expression
resulted in hypertrophic crypt formation, expanded stem
cell populations, and increased intermediate cells in the
proximal small intestine. Expression of both HER2 and APC
mutations resulted in enhanced proliferation of the crypt
compartment. This work is the first to generate a Tg
mouse model for HER2 activating mutations and charac-
terizes the effect of HER2V777L on the intestinal epithelium.
Our results suggest an epithelial intrinsic role of
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HER2V777L on hyperproliferation and enhanced intestinal




Generation of Tg Mice Expressing HER2V777L in the
Intestinal Epithelium. HER2V777L Tg were generated us-
ing TALEN-based genome editing. ROSA26 specific TALENs
were designed using the ZiFit targeter.22 The TALEN kit
used for TALEN assembly was a gift from Keith Joung
(Addgene kit # 1000000017; Addgene, Watertown, MA).
DNA fragments encoding ROSA TALEN repeat arrays were
cloned into plasmid pJDS71. ROSA TALENs plasmids were
linearized for in vitro transcription with EcoRI and TALENs
RNA was synthesized using the mMessage mMachine T7
Ultra kit (Ambion, Austin, TX) and purified with Megaclear
columns (Ambion).
The cassette of interest was synthesized (Genscript,
Piscataway, NJ) and introduced into the mouse genome via
pronuclear injection of in vitro transcribed TALENs RNA
and ROSA donor DNA. Founders with correctly targeting
mutant alleles are identified using long PCR with ROSA
specific oligos outside of the homology arms. Founders were
bred to WT to generate heterozygous F1 offspring. Analysis
of F1 offspring via long PCR confirms germline transmission
of the correctly targeted allele. Primers for genotyping
heterozygous offspring are the following:
ROSA-green-WT-F1: 50 GTT ATC AGT AAG GGA GCT GCA
GTG GAG TAG 30
ROSA-green-WT-R1: 50 CCG AAA ATC TGT GGG AAG TCT
TGT CCC TCC 30
CAG-R2: 50 CTC CAC CCA TTG ACG TCA ATG GAA AGT
CCC 30
Lgr5-Cre ERT2 and Villin-Cre ERT2 Mice. Lgr5-EGFP-
Ires-CreERT2 mice were purchased from the Jackson Lab-
oratory [Bar Harbor, ME; B6.129P2-Lgr5tm1(cre/ERT2)
Cle/J; 008875] and Villin-Cre ERT2 mice were a gift from
Blair Madison.23 APCmin mice were also purchased from the
Jackson Laboratory (C57BL/6J-ApcMin/J; 002020). All ani-
mal work was approved by the Washington University
School of Medicine Animal Studies Committee.
Induction of Recombination
Expression of the transgene was driven by Cre-
recombination of the lox-stop-lox sites. We crossed
HER2V777L Tg mice to Lgr5-EGFP-IRES-CreERT2 or Villin-
CreERT2 mice to activate HER2 expression in intestinal
stem cells or the intestinal epithelial cells, respectively. To
study the contribution of APC loss on the intestinal epithe-
lium, Lgr5-Cre; HER2V777L Tg mice were crossed with het-
erozygous APCmin mice to generate Lgr5-Cre; APCmin;
HER2V777L Tg mice.
For CreERT2-mediated recombination, 8-week-old to 5-
month-old mice were injected intraperitoneally with
tamoxifen (2 mg/injection; Sigma-Aldrich, St. Louis, MO)
dissolved in corn oil for 3 consecutive days and sacrificed 10
days after the last tamoxifen injection. The 10-day time
point was chosen for 2 reasons. First, we wanted to allow
adequate time for transit of cells from the crypt base to the
tips of the villus. Second, we previously treated Villin-
CreERT2; HER2V777L Tg mice with tamoxifen and moni-
tored them for 1 month, but the mice died from either in-
testinal blockage or malabsorption caused by the marked
villus hypertrophy, which constricted the intestinal lumen.
Therefore, to avoid mouse deaths, a short-term time point
posttamoxifen induced Cre/lox recombination was chosen.
Lgr5-Cre; HER2V777L Tg mice showed variegated expression
of the HER2 transgene with 60% of the intestinal crypts and
villi having strong HER2 expression. Quantification of crypt




The proximal small intestine, distal small intestine, and
colon were embedded in 2% agar, paraffin embedded, and
5-mm sections were prepared (Digestive Diseases Research
Core, Washington University School of Medicine). For his-
tology, unstained slides were stained for the indicated an-
tibodies via immunohistochemistry (Department of
Immunology and Pathology, Washington University School
of Medicine). Immunohistochemistry was performed by a
standard protocol on Ventana automated stainer (Ventana
Medical Systems, Tucson, AZ). Antigen retrieval was per-
formed for HER2/neu (rabbit monoclonal, clone 4B5)
(Ventana Medical Systems) with CC1 buffer (Cell Condi-
tioning 1; EDTA-based buffer pH 8.0; Ventana Medical Sys-
tems), for KI-67 2 ug/mL (rabbit monoclonal, clone 30-9;
Ventana Medical Systems) with CC1 buffer (Cell Condition-
ing 1; EDTA-based buffer pH 8.0, Ventana Medical Systems)
for lysozyme (rabbit polyclonal) (Cell Marque, Rocklin, CA)
with CC1 buffer (Cell Conditioning 1; EDTA-based buffer pH
8.0; Ventana Medical Systems).
Biotin-free multimer technology system, based on direct
linkers between peroxidase and secondary antibodies
(ultraView Universal DAB Detection Kit; Ventana Medical
Systems) were used as detection kit.
Immunofluorescence of Paraffin-Embedded
Sections
Slides were de-paraffinized and subjected to heat-
induced antigen retrieval in Trilogy (MilliporeSigma, Bur-
lington, MA) solution for 20 minutes. Slides were blocked in
phosphate-buffered saline containing 1% bovine serum al-
bumin, 5% goat serum, and 0.1% Triton-X 100 for 1 hour at
room temperature, and then treated with primary anti-
bodies at desired dilutions for 16 hours at 4C. Slides were
then washed 3 times in phosphate-buffered saline and
incubated with secondary antibodies conjugated with fluo-
rophores (Thermo Fisher Scientific, Waltham, MA) for 1
hour at room temperature.24 Primary antibodies used in the
study include rabbit MUC2 (Santa Cruz Biotechnology, Dal-
las, TX; sc-15334), mouse MMP7 (R&D Systems, Minneap-
olis, MN; AF2967-SP), phospho-p44/42 MAPK (Erk1/2)
(Thr202/204) (Cell Signaling Technology, Danvers, MA;
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#9101). Secondary antibodies used included anti-rabbit IgG
(HþL) Alexa Fluor 555 (Invitrogen, San Diego, CA; A-
31572), anti-goat IgG (HþL) Alexa Fluor Plus 488 (Invi-
trogen; A32814). Nucleic acid was staining with DAPI
(Sigma-Aldrich; F6057).
Establishment of Intestinal Organoid and Colon
Organoid Cultures
Isolation of crypts from the jejunum of Lgr5-Cre;
HER2V777L Tg and HER2V777L Tg littermate mice were per-
formed as described.25 Isolated intestinal crypts were
embedded in Matrigel (BD Biosciences, San Jose, CA) and
seeded in 6-well plates. The cells were overlaid with 2 mL/
well basal culture medium (advanced Dulbecco’s modified
Eagle medium/F12 supplemented with penicillin/strepto-
mycin, 10mmol/L HEPES, Glutamax, 1N2, 1B27 (all
from Thermo Fisher Scientific), and containing EGF (Sigma-
Aldrich), noggin, and Rspo1 (noggin and R-spondin condi-
tioned media were a gift from Blair Madison). For colon
organoid generation, crypts were isolated from the proximal
colon of Lgr5-Cre; HER2V777L Tg and HER2V777L Tg litter-
mate mice and cultured in 50% L-WRN media as described
previously.26
Transmission Electron Microscopy
For ultrastructural analyses, samples were fixed in 2%
paraformaldehyde/2.5% glutaraldehyde (Polysciences,
Warrington, PA) in 100 mM sodium cacodylate buffer, pH
7.2 for 2 hours at room temperature and then overnight at
4C. Samples were washed in sodium cacodylate buffer at
room temperature and postfixed in 1% osmium tetroxide
(Polysciences) for 1 hour. Samples were then rinsed
extensively in dH20 prior to en bloc staining with 1%
aqueous uranyl acetate (Ted Pella, Redding, CA) for 1 hour.
Following several rinses in dH20, samples were dehy-
drated in a graded series of ethanol and embedded in
Eponate 12 resin (Ted Pella). Sections of 95 nm were cut
with a Leica Ultracut UCT ultramicrotome (Leica Micro-
systems, Bannockburn, IL), stained with uranyl acetate and
lead citrate, and viewed on a JEOL 1200 EX transmission
electron microscope (JEOL USA, Peabody, MA) equipped
with an AMT 8-MP digital camera and AMT Image Capture
Engine V602 software (Advanced Microscopy Techniques,
Woburn, MA).
Quantitative RT-PCR
RNA was isolated from the jejunum of the Lgr5-Cre;
HER2V777L Tg mice and 2 ug of RNA were reverse tran-
scribed into complementary DNA using the complementary
DNA reverse transcription kit (Applied Biosystems, Foster
City, CA). qRT-PCR was performed with an ABI Prism 7300
Sequence Analyzer using SYBR green fluorescence probes.
Quantification cycle (Cq) of genes of interest were normal-
ized to the average Cq of 18s ribosomal RNA (reference
gene) and expressed as relative mRNA levels. Primers were
a gift from Matthew Ciorba27 and primer sequences are the
following:





























Genomic Analysis of ERBB2 and APC Co-
occurring Mutations
Mutations were extracted from The Cancer Genome Atlas
Unified Ensemble MC3 Call Set.14 Colon adenocarcinoma
(COAD) or rectum adenocarcinoma (READ) patients were
extracted from the MC3 mutation file, resulting in a total of
559 patients with 223,860 mutations (excluding the
following mutation types: Silent, Intron, RNA, 50 flank, 30
flank, IGR, translation start site, 30 UTR, and 50 UTR).
Statistical Analysis
DataarepresentedasmeansandSEM.TheStudent t test and
the Mann-Whitney U test was used to analyze data with 2
groups. For statistical analysis, GraphPad Prism version 7
(GraphPad Software, San Diego, CA) was used. A P value <.05
was consideredstatistically significant. All authorshadaccess to
the studydata and reviewedandapproved thefinalmanuscript.
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